LN-145

BIOLOGICAL9 trials

Sponsors

Iovance Biotherapeutics Inc., Iovance Biotherapeutics, Inc., Karam Khaddour, MD, MS

Conditions

Cervical CarcinomaCutaneous Squamous Cell CarcinomaMerkel Cell CarcinomaMetastatic Cutaneous Squamous Cell CarcinomaMetastatic MelanomaMetastatic Non Small Cell Lung CancerMetastatic Non-Small-Cell Lung CancerNeoplasm

Phase 2

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

CompletedNCT03083873

Iovance Biotherapeutics, Inc.Squamous Cell Carcinoma of the Head and Neck

Start: 2017-01-09End: 2022-08-08Updated: 2023-10-12

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

TerminatedNCT03108495

Iovance Biotherapeutics, Inc.Cervical Carcinoma

Start: 2017-06-22End: 2025-08-22Updated: 2025-09-17

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

WithdrawnNCT03419559

Iovance Biotherapeutics, Inc.Non Small Cell Lung Cancer

Start: 2018-02-28End: 2024-12-31Updated: 2019-04-16

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

RecruitingNCT03645928

Iovance Biotherapeutics, Inc.Metastatic Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck

Start: 2019-05-07End: 2029-08-09Target: 245Updated: 2025-06-19

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

RecruitingNCT04614103

Iovance Biotherapeutics, Inc.Metastatic Non Small Cell Lung Cancer

Start: 2021-05-07End: 2031-12-31Target: 170Updated: 2025-11-12

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma

CompletedCTIS2024-510634-41-00

Iovance Biotherapeutics Inc.metastatic, or persistent Cervical Carcinoma, Recurrent

Start: 2018-02-22End: 2024-09-21Target: 95Updated: 2025-05-09

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer

RecruitingCTIS2024-510778-26-00

Iovance Biotherapeutics Inc.Metastatic Non-Small-Cell Lung Cancer

Start: 2025-12-19Target: 115Updated: 2025-11-26

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors

Active, not recruitingCTIS2024-510779-39-00

Iovance Biotherapeutics Inc.Neoplasm

Start: 2018-12-19Target: 95Updated: 2026-01-21

TIL Therapy in cSCC and MCC

RecruitingNCT07288073

Karam Khaddour, MD, MSCutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma +1

Start: 2026-02-10End: 2029-06-29Target: 14Updated: 2026-02-13

Related Papers

Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Journal for ImmunoTherapy of Cancer2025-08-013 citations

Phase 2, multicenter study of frontline maintenance therapy with lifileucel plus pembrolizumab in advanced non-small cell lung cancer.

Journal of Clinical Oncology2025-05-281 citations

Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A.

Journal of Clinical Oncology2024-06-0114 citations

Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer

Future Oncology2023-05-185 citations

Abstract CT130: Trial in progress: A phase 2 multicenter study (IOV-LUN-202) of autologous tumor-infiltrating lymphocyte (TIL) cell therapy (LN-145) in patients with metastatic non-small cell lung cancer (mNSCLC)

Cancer Research2022-06-154 citations

Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naïve and -experienced patients with metastatic melanoma treated with lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy.

Journal of Clinical Oncology2022-06-014 citations

Abstract P050: Trial in progress: A phase 2 multicenter study of autologous tumor-infiltrating lymphocyte (TIL, LN-145) cell therapy in patients with metastatic non-small cell lung cancer (mNSCLC)

Molecular Cancer Therapeutics2021-12-01

492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers

Regular and Young Investigator Award Abstracts2021-11-0134 citations

458 First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)

Regular and Young Investigator Award Abstracts2021-11-0124 citations

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types

Journal for ImmunoTherapy of Cancer2021-10-0161 citations

Abstract CT235: A Phase 2, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumors

Cancer Research2021-07-011 citations

Abstract CT246: A phase 2 multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN-145) cell therapy in patients with metastatic non-small cell lung cancer (mNSCLC)

Cancer Research2021-07-01

Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma.

Journal of Clinical Oncology2021-05-201 citations

353 Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC

Regular and Young Investigator Award Abstracts2020-11-0115 citations

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma

Journal for ImmunoTherapy of Cancer2020-07-0153 citations

Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.

Journal of Clinical Oncology2019-05-20130 citations

A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors.

Journal of Clinical Oncology2019-05-205 citations

A phase II study of autologous tumor infiltrating lymphocytes (TIL; LN-144/LN-145) in patients with solid tumors

Annals of Oncology2018-12-01

Abstract CT170: A phase II, multicenter study to evaluate the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-145) for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Cancer Research2018-07-011 citations

Abstract CT172: A phase 2 multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent metastatic or persistent cervical carcinoma

Cancer Research2018-07-01

3 more papers not shown